کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3907506 | 1599309 | 2016 | 13 صفحه PDF | دانلود رایگان |
• Many diseases of prematurity involve inflammation and dysfunctional growth.
• Diseases of prematurity are suitable candidates for cell-based treatment strategies.
• Clinical data for cell-based treatments in neonates are still very limited.
• Experimental findings are promising, but many issues remain unsolved.
Infants born preterm face a number of challenges. Depending on the degree of prematurity, they are at a risk of developing several specific conditions and diseases related to organ immaturity and complications of long-term neonatal intensive care. Various organ systems are affected, such as the lung, resulting in bronchopulmonary dysplasia (BPD); the vascular system, resulting in pulmonary hypertension; the brain, with the risk of intracranial hemorrhage; the eye with retinopathy of prematurity; and the gut, manifesting in the severe complication of necrotizing enterocolitis. A common hallmark for all these prematurity-related conditions is that inflammation seems to be a major driving force in the pathogenesis, and that injury repair is essential for recovery and long-term health. In addition, the available treatment options are often only supportive, not curative. This chapter reviews the recent advances of stem cell therapy that have opened up new possibilities to restore organ function following prematurity.
Journal: Best Practice & Research Clinical Obstetrics & Gynaecology - Volume 31, February 2016, Pages 99–111